Drug Trial Radar · NCT01041001
Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury
Last checked: Nov 20, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Feb 2009
Primary completion
Dec 2010
Study completion Jan 2011
Sponsor
- Lead sponsor
- Medipost Co Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess and compare the safety and efficacy of the allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product (Cartistem®) to that of a microfracture treatment in patients with articular cartilage defect or injury.
Conditions
- Cartilage Injury
- Osteoarthritis
Interventions
CartistemBiological
allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
Microfracture treatmentProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.Time frame: Week 0 and 48
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Inha University Hospital
Incheon, South Korea
Hanyang University Medical Center
Seoul, South Korea
Seoul Veterans Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Ewha Womans University Mokdong Hospital
Seoul, South Korea
Gachon University Gil Hospital
Incheon, Gyunggido, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.